期刊
JOURNAL OF CELLULAR PHYSIOLOGY
卷 226, 期 9, 页码 2338-2349出版社
WILEY-BLACKWELL
DOI: 10.1002/jcp.22576
关键词
-
资金
- NSC [96-2116-M-039-001-MY3, NSC 98-3114-B-001-001]
- Taiwan Department of Health Clinical Trial Research Center of Excellence [DOH 99-TD-B-111-004]
- Health Cancer Research Center of Excellence [DOH-99-TD-C-111-005]
Honokiol (HNK) is a phenolic compound isolated from the bark of houpu (Magnolia officinalis), a plant widely used in traditional Chinese and Japanese medicine. While substantial evidence indicates that HNK possesses anti-inflammatory activity, its effect on dendritic cells (DCs) during the inflammatory reaction remains unclear. The present study investigates how HNK affects lipopolysaccharide (LPS)-stimulated human monocyte-derived DCs. Our experimental results show that HNK inhibits the inflammatory response of LPS-induced DCs by (1) suppressing the expression of CD11c, CD40, CD80, CD83, CD86, and MHC-II on LPS-activated DCs, (2) reducing the production of TNF-alpha, IL-1 beta, IL-6, and IL-12p70 but increasing the production of IL-10 and TGF-beta 1 by LPS-activated DCs, (3) inhibiting the LPS-induced DC-elicited allogeneic T-cell proliferation, and (4) shifting the LPS-induced DC-driven Th1 response toward a Th2 response. Further, our results show that HNK inhibits the phosphorylation levels of ERK1/2, p38, JNK1/2, IKK alpha, and I kappa B alpha in LPS-activated DCs. Collectively, the findings show that the anti-inflammatory actions of HNK on LPS-induced DCs are associated with the NF-kappa B and mitogen-activated protein kinase (MAPK) signaling pathways. J. Cell. Physiol. 226: 2338-2349, 2011. (C) 2010 Wiley-Liss, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据